We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals

104 hedge funds and large institutions have $280M invested in Lexicon Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 30 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

329% more call options, than puts

Call options by funds: $296K | Put options by funds: $69K

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

27% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 30

6% more funds holding

Funds holding: 98 → 104 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3.46% less ownership

Funds ownership: 81.07% → 77.61% (-3.5%)

55% less capital inflows, than outflows

Capital inflows: $3.42M | Capital outflows: $7.63M

Holders
104
Holders Change
+6
Holders Change %
+6.12%
% of All Funds
1.67%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
38
Reduced
30
Closed
7
Calls
$296​K
Puts
$69​K
Net Calls
+$227​K
Net Calls Change
+$27​K

LXRX Hedge Fund Activity: Q4 2022 in Review

104 of the 6,245 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2022, worth a combined $280M — down 22% from $357M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new LXRX positions and 7 closed out — a net gain of 7 holders — while 38 added to existing stakes and 30 trimmed.

The largest buyer was Millennium Management, adding an estimated $576K. The largest seller was Point72 Asset Management, cutting an estimated $4.83M.

  • 104 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2022, up from 98 in Q3 2022.
  • Funds reported $280M of Lexicon Pharmaceuticals stock for Q4 2022, down 22% quarter-over-quarter.
  • 14 funds opened new Lexicon Pharmaceuticals positions in Q4 2022 and 7 closed out, a net change of +7 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $576K added.
  • The largest Lexicon Pharmaceuticals seller in Q4 2022 was Point72 Asset Management, an estimated $4.83M sold.

Based on aggregated 13F filings for Q4 2022.